Table 2 The mean number of inpatient bed days and outpatient visits within 5 years of the index date (date of response evaluation + 90 days) for DLBCL survivors and matched comparators without lymphoma.
Mean number of bed days | Mean number of outpatient visits | ||||
|---|---|---|---|---|---|
DLBCL survivors | DLBCL survivors | Comparators | DLBCL survivors | Comparators | |
All patients | 1446 | 10.3 (9.3–11.3) | 8.4 (7.9–8.8) | 4.2 (4.0–4.4) | 3.8 (3.7–3.9) |
Sex | |||||
Females | 648 | 9.9 (8.5–11.2) | 7.7 (7.1–8.3) | 4.3 (4.0–4.6) | 3.8 (3.6–3.9) |
Males | 798 | 10.7 (9.3–12.0) | 8.9 (8.3–9.5) | 4.1 (3.8–4.3) | 3.8 (3.7–3.9) |
Age | |||||
18–55 | 326 | 6.2 (4.5–7.7) | 4.4 (3.4–5.2) | 3.5 (3.1–3.8) | 2.6 (2.4–2.7) |
56–65 | 367 | 10.2 (8.1–12.1) | 7.2 (6.4–8.0) | 3.9 (3.6–4.3) | 3.3 (3.2–3.4) |
66–75 | 523 | 11.4 (10.0–12.9) | 9.7 (9.0–10.4) | 4.7 (4.3–5.0) | 4.6 (4.4–4.7) |
>75 | 230 | 14.8 (11.3–17.8) | 13.9 (12.8–14.8) | 4.8 (4.2–5.3) | 4.7 (4.5–5.0) |
Stage | |||||
Limited (I–II) | 485 | 9.5 (7.7–11.1) | 8.2 (7.4–9.0) | 4.3 (4.0–4.6) | 3.7 (3.6–3.9) |
Advanced (III–IV) | 953 | 10.8 (9.5–12.0) | 8.4 (7.9–8.9) | 4.2 (3.9–4.4) | 3.8 (3.7–3.9) |
ECOG PS | |||||
0 | 783 | 8.7 (7.3–9.9) | 7.5 (6.9–8.0) | 4.0 (3.8–4.3) | 3.6 (3.5–3.7) |
1–4 | 656 | 12.4 (10.9–13.7) | 9.1 (8.5–9.8) | 4.4 (4.2–4.7) | 4.0 (3.8–4.1) |
